Antineoplastic Agents, Immunological Clinical Trials in Pittsburgh, Pennsylvania

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma